Bay­er re­calls one lot of sol­id tu­mor drug Vi­t­rakvi af­ter find­ing mi­cro­bial con­t­a­m­i­na­tion

Bay­er is vol­un­tar­i­ly re­call­ing a batch of its oral sol­id tu­mor drug Vi­t­rakvi be­cause of mi­cro­bial con­t­a­m­i­na­tion, just weeks af­ter with­draw­ing a sep­a­rate fol­lic­u­lar lym­phoma drug from the mar­ket.

The com­pa­ny said Fri­day it found Peni­cil­li­um bre­vi­com­pactum dur­ing rou­tine sta­bil­i­ty test­ing and is pulling 100 mL glass bot­tles that were dis­trib­uted to whole­salers and spe­cial­ty phar­ma­cies across the US be­tween Jan. 3, 2023, and Feb. 13, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER